Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 7,630 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Age Related Cataracts
Interventions: 0.4% ZOC2017217, Control; Drug
Lead sponsor: Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 21
States / cities: Scottsdale, Arizona • Tucson, Arizona • Glendale, California + 18 more

Conditions: Breast Cancer
Interventions: nivolumab, paclitaxel (PTX), nivolumab placebo, anthracycline, cyclophosphamide, Endocrine Therapy, Surgery; Biological · Drug · Other + 1 more
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 30
States / cities: Mobile, Alabama • Greenbrae, California • Whittier, California + 27 more

Conditions: Degenerative Disc Disease
Interventions: Rexlemestrocel-L + HA mixture, Saline; Drug
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 37 more

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 40,805 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 188
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 150 more

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: Not listed
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 192
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Glendale, Arizona + 162 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Carfilzomib, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 12
States / cities: Fountain Valley, California • Denver, Colorado • Plainville, Connecticut + 9 more

Conditions: Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Interventions: HBI-8000 in combination with nivolumab, Placebo in combination with nivolumab; Drug
Lead sponsor: HUYABIO International, LLC.; Industry
Eligibility: 12 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 31
States / cities: Bakersfield, California • La Jolla, California • Pasadena, California + 28 more

Conditions: Hepatitis C
Interventions: SOF, VEL, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 50
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 38 more

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: Adhansia XR; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Little Rock, Arkansas • Colorado Springs, Colorado • Jacksonville, Florida + 12 more

Conditions: Ventricular Arrhythmia, Tachycardia
Interventions: Defibrillation using EV-ICD; Device
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 57
States / cities: Huntington Park, California • Redwood City, California • San Diego, California + 45 more

Conditions: Meningococcal Infection (Healthy Volunteers)
Interventions: Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Blood sample; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 59 Years and older
Enrollment: 471 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 33
States / cities: Chandler, Arizona • San Diego, California • Waterbury, Connecticut + 27 more

Conditions: Rapid Eye Movement Sleep Behavior Disorder, Parkinson Disease
Interventions: Immediate Release Melatonin, Extended Release Melatonin; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Migraine
Interventions: Atogepant 60 mg, Propranolol 160 mg, Topiramate 100 mg; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1,335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 37
States / cities: Hazel Green, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 30 more

Conditions: Anaplastic Medulloblastoma, Medulloblastoma
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Cyclophosphamide, Filgrastim, Isotretinoin, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate; Procedure · Drug · Biological + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 22 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 170
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more

Conditions: Proteinuria, Idiopathic Membranous Nephropathy
Interventions: Repository Corticotropin Injection, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 14
States / cities: Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort, Cortef, Placebo; Drug · Other
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more

Conditions: Neoplasms, Gastric Cancer
Interventions: Standard of Care Procedure as described in ARM; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hospitalized Elderly
Interventions: Ready to Drink Flavored Beverage, Ready to drink flavored beverage w/ AN 777; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 65 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 115
States / cities: Auburn, Alabama • Birmingham, Alabama • Huntsville, Alabama + 100 more

Conditions: Pruritus
Interventions: Dupilumab 300Mg Solution for Injection; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 2,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 843
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 550 more

Conditions: Enterocolitis Clostridium Difficile Recurrent
Interventions: RBX2660 (microbiota suspension), Placebo; Biological · Other
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 19
States / cities: Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 15 more

Conditions: Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration; Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 928 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 15
States / cities: Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 11 more

Conditions: Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Interventions: Ranibizumab, Saline; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Phoenix, Arizona • Irvine, California • Loma Linda, California + 58 more

Search by objective public record fields.

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

Enlighten Study: The EV-ICD Post Approval Registry

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia

A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)